Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A liposarcoma that arises from the ovary and is composed of round to oval mesenchymal cells, small signet ring lipoblasts, and a rich network of capillaries in a myxoid stroma.
No clinical trials have been registered for ovarian myxoid liposarcoma.
2 publications have been identified in PubMed for ovarian myxoid liposarcoma. Research spans Review / Meta-Analysis (100%).
Knafler G (2025). [PMID: 39970827](https://pubmed.ncbi.nlm.nih.gov/39970827/). *Cancer Treat Rev*. [Review / Meta-Analysis]
Kim M (2024). [PMID: 39026440](https://pubmed.ncbi.nlm.nih.gov/39026440/). *J Pathol Transl Med*. [Review / Meta-Analysis]
Data assembled from 2 of 12 sources · Last updated Sep 19, 2026, 11:55 PM UTC
AI-curated news mentioning ovarian myxoid liposarcoma
Updated May 16, 2026
A Phase 2 clinical trial, DOREMY, investigates the effects of dose reduction in preoperative radiotherapy for myxoid liposarcoma. The study aims to optimize treatment while maintaining efficacy in this rare cancer type.
A recent case report details myxoid liposarcoma of the sigmoid mesocolon, contributing to the understanding of this rare tumor type. The review of literature provides insights into its clinical presentation and management.